Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Attention Deficit Disorder: early-phase trial registry

2 of 5 indexed Attention Deficit Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Attention Deficit Disorder: 5 US clinical trials tracked, 2 recruiting.

Attention Deficit Disorder is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Rochester Center for Behavioral Medicine, running 1 of these trials.

Enrollment posture brief

Registry condition attention-deficit-disorder

OPEN 2 | RECR 40% | LATE 1 | EARLY 2 | RANK #3391 | SPON 1

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Attention Deficit Disord (th…40%
Open-enrollment share among volume-matched conditions near Attention Deficit Disorder

Attention Deficit Disorder lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Attention Deficit Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Attention Deficit Disorder is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Attention Deficit Disorder research.

    Rochester Center for Behavioral Medicine accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Attention Deficit Disorder trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Attention Deficit Disorder research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 4 1

Named interventions

Most-linked intervention names on Attention Deficit Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
MIP Protocol Behavioral
1 trials
Lisdexamfetamine Drug
1 trials
Dyanavel XR Drug
1 trials
Sham transcranial direct current stimulation (tDCS) Device
1 trials
1 mA transcranial direct current stimulation (tDCS) Device
1 trials
2 mA transcranial direct current stimulation (tDCS) Device
1 trials

US sites by state

Facility locations filed on Attention Deficit Disorder trials. A trial with sites in several states counts in each.

New York 2 trials
Pennsylvania 1 trials
Michigan 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Attention Deficit Disorder page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Attention Deficit Disorder condition card totals 5 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.